Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 13:2020:8678945.
doi: 10.1155/2020/8678945. eCollection 2020.

Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer

Tian Yun  1 , Sunan Wang  2 , Bo Jiang  3 , Changsong Wang  1 , Nianlong Meng  1 , Xutao Yuan  1 , Yangkun Wang  4
Affiliations

Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer

Tian Yun et al. J Oncol. .

Abstract

Objective: To explore the relationship between the HER2 gene and PD-1/PD-L1 in gastric cancer and its significance.

Methods: Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) were used to detect HER2 protein expression, HER2 gene amplification, and PD-1/PD-L1 expression in 78 cases of gastric cancer.

Results: The expression rate of HER2 protein was 43.6% (34/78), of which 19.4% (14/78) were HER2 3+, 14.1% (11/78) were HER2 2+, and 11.5% (9/78) were HER2 1+. The results showed that 19.2% (15/78) of samples had HER2 gene amplification, 3.8% (3/78) of samples had a HER2/CEP17 ratio <2.0, and 19.2% (15/78) of samples had HER2 gene amplificationf and HER2 copy/cell ≥6.0, as detected by FISH. The positive rate of PD-L1 was 38.5% (30/78) in gastric cancer cells and 50.0% (39/78) in interstitial lymphocytes. The expression of the HER2 gene, PD-L1, and PD-1 in gastric cancer was correlated with the stage and lymph node metastasis of gastric cancer (P < 0.05).

Conclusions: The combined detection of the HER2 gene and PD-1/PD-L1 in gastric cancer provides an important reference index for the prognosis of gastric cancer and the benefit of targeted antitumor drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest to this work.

Figures

Figure 1
Figure 1
(a) Gastric papillary adenocarcinoma, HER2 positive 3+ extensive staining (X200); (b) Gastric mixed adenocarcinoma, mucinous adenocarcinoma, and papillary adenocarcinoma, HER2 positive 3+ partial staining (X40); (c) gastric tubular papillary adenocarcinoma, HER2 positive 3+ focal staining (X200), Envision method.
Figure 2
Figure 2
FISH method to detect HER2 gene amplification, red as probe signal, green as chromosome 17: (a) HER2 gene cluster amplification; (b) HER2 gene large particle amplification; (c) HER2 gene dot amplification; (d) HER2 gene high polymorph amplification.
Figure 3
Figure 3
Gastric adenocarcinoma. (a) Gastric mucinous adenocarcinoma shows positive PD-L1 expression (X200). (b) Poorly differentiated gastric adenocarcinoma shows positive PD-L1 expression (X200), Envision method.
Figure 4
Figure 4
Gastric adenocarcinoma. (a) Interstitial lymphocytes of mucinous adenocarcinoma show positive expression of PD-1 (X200). (b) Interstitial lymphocytes of papillary gastric adenocarcinoma show negative expression of PD-1 (X200), Envision method.
See this image and copyright information in PMC

References

    1. Guilford P., Blair V., More H., Humar B. A short guide to hereditary diffuse gastric cancer. Hereditary Cancer in Clinical Practice. 2007;5(4):183–194. doi: 10.1186/1897-4287-5-4-183. - DOI - PMC - PubMed
    1. Kadar Z., Jung I., Orlowska J., et al. Geographic particularities in incidence and etiopathogenesis of sporadic gastric cancer. Polish Journal of Pathology. 2015;3(3):254–259. doi: 10.5114/pjp.2015.54959. - DOI - PubMed
    1. Li S. S., Udelsman B. V., Parikh A., et al. Impact of postoperative complication and completion of multimodality therapy on survival in patients undergoing gastrectomy for advanced gastric cancer. Journal of American College of Surgeons. 2020;230(6):912–924. doi: 10.1016/j.jamcol/surg.2019.12.038. - DOI - PubMed
    1. Felismino T. C., De Oliveira A. C. F., Alves A. C. F., et al. Primary tumor location is a predictor of poor prognosis in patients with locally advanced esophagogastric cancer treated with perioperative chemotherapy. Journal of Gastrointestinal Cancer. 2019;51(2):484–490. doi: 10.1007/s12029-019-00258-1. - DOI - PubMed
    1. Wang Y. K., Gao C. F., Yun T., et al. Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization. Molecular Cytogenetics. 2011;4(1):p. 14. doi: 10.1186/1755-8166-4-14. - DOI - PMC - PubMed

LinkOut - more resources